EPL Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Unlock the Full Balanced Scorecard for Deeper Strategic Insight
This EPL Balanced Scorecard Analysis gives you a clear, company-specific view of EPL's strategic priorities across financial, customer, internal process, and learning and growth perspectives. What you see on this page is a real preview of the actual analysis, not just marketing text, so you can review the format and content before buying. Purchase the full version for the complete ready-to-use report.
Benefits
Robust Cash Flow Tracking
In fiscal 2025, the scorecard should keep EPL focused on its high-share oral care line, which can turn steady demand into cash reserves. Tracking asset utilization and cash conversion helps management spot where factory, inventory, and receivables use is strongest. That supports self-funded growth into higher-margin specialized packaging, cutting the need for expensive debt.
Recyclable Portfolio Growth
EPL tracks Platina and Ecopack adoption by market, so R&D spend is tied to products that can replace non-recyclable tubes. This supports EPL's FY2025 goal of shifting its full portfolio to 100% recyclable materials, a move that matters as the global packaging market keeps tightening rules on plastic waste. When rollout and recycle-rate metrics rise together, portfolio growth becomes both greener and easier to defend with customers.
Operational Quality Benchmarking
With 20+ manufacturing facilities, the internal process view gives EPL one scorecard for rejection rates and uptime across all plants. In fiscal 2025, that lets managers compare top U.S. sites with emerging-market plants fast and copy the best run settings, quality checks, and maintenance plans. One standard view cuts variation, lifts throughput, and makes weak plants visible early.
Strategic Pharma Market Penetration
EPL's Balanced Scorecard ties pharma market penetration to certified quality systems like ISO 15378 and customer approvals, so the firm can win higher-margin packaging deals. In FY25, the pharma packaging push matters because India's pharmaceutical market was about $65 billion, and even small share gains can shift revenue mix. Tracking tube volumes for ointments and gels also lowers dependence on toothpaste, EPL's mature core.
Enhanced Customer Relationship Depth
EPL's 2025 focus on key account metrics supports longer contracts with Colgate-Palmolive and Unilever, two FMCG leaders that buy at global scale. In FY2025, Colgate-Palmolive reported net sales of $20.1 billion, so even small share gains on packaging can matter.
Tracking joint innovation projects helps EPL move from vendor to partner, which raises switching costs and can lift revenue visibility across multi-year deals. That depth also supports pricing power when service and design work are tied to customer launches.
EPL's Scorecard Turns Demand Into Cash and Sustainable Growth
In FY2025, EPL's Balanced Scorecard helps turn strong oral-care demand into cash, while keeping factory use, inventory, and receivables under control. It also links recyclable-packaging R&D to market rollout, so growth is tied to products customers can buy. The scorecard improves plant quality across 20+ sites and supports pharma and key-account wins, including Colgate-Palmolive's $20.1 billion sales base.
| Benefit | FY2025 data |
|---|---|
| Cash generation | High oral-care demand |
| Growth mix | 100% recyclable goal |
| Scale | 20+ facilities |
| Customer value | Colgate-Palmolive $20.1b sales |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Volatile Polymer Margin Erosion
Volatile polymer margin erosion is a weak spot in EPL's scorecard because it often misses 5% to 15% swings in raw plastic resin prices in real time. In 2025, resin costs stayed sensitive to crude-linked feedstock moves, so a 10% input jump can wipe out efficiency gains fast if pricing resets lag. That lag makes internal targets look healthy while EBITDA and gross margin move the other way. In high-inflation periods, the gap can distort capital and pricing decisions.
Reporting Latency Across Regions
Reporting across Asia, Europe, and the US can lag by 15+ time zones, so monthly reviews often close before the latest plant, logistics, or labor data is in. That delay can hide supply chain bottlenecks and wage shifts in time to act. In EPL, slow consolidation turns balanced scorecard KPIs into backward-looking numbers, not live signals.
Regulatory Compliance Data Gaps
As sustainability rules tighten, EPL still cannot fully verify 100% Post-Consumer Recycled content in every tube because supplier data often stops at tier 1. Under the EU Corporate Sustainability Reporting Directive, reporting pressure now reaches about 50,000 companies, but sub-tier traceability remains patchy.
This weakens the scorecard because missing chain data can hide material risk, raise audit costs, and slow compliance sign-off. It also makes it hard to quantify the full environmental impact across resin, cap, and packaging inputs.
Low Bargaining Power Pressure
Low bargaining power pressure is a real drag in EPL's customer perspective because multinational FMCG buyers can push hard on price, service levels, and credit terms. That makes it difficult to lift satisfaction scores without giving discounts or extras that weaken margins and clash with financial goals.
In practice, even a small price cut on high-volume contracts can erase a meaningful share of operating profit, so customer wins do not always translate into value creation. This leaves EPL stuck between retention and profitability.
High Capital Investment Cycles
A scorecard that pushes asset turnover can underfund big tube-line upgrades, and a single new line can cost $10 million or more. That can delay next-gen material science and biodegradable polymer work, even as brands face tighter 2025 packaging rules. Short payback goals help today's output, but they can block the capital cycle needed for long-life capacity and better margins.
EPL Scorecard: Resin Swings, Reporting Lag, and PCR Gaps
EPL's scorecard drawbacks stay tied to 2025 resin cost swings, slow cross-region reporting, and weak sub-tier PCR traceability. A 10% resin jump can still outrun pricing resets, while 15+ time-zone delays make KPI reviews lag live plant and logistics issues. Under CSRD, traceability gaps also raise audit load and compliance risk.
| Drawback | 2025 signal |
|---|---|
| Margin pressure | 5% to 15% resin swings |
| Reporting lag | 15+ time zones |
| Traceability gap | About 50,000 CSRD firms |
What You See Is What You Get
EPL Reference Sources
This is the actual EPL Balanced Scorecard analysis document you'll receive after purchase-no samples, just the real file. The preview below comes directly from the full report, so what you see is exactly what you get. Once you complete checkout, the entire detailed version is unlocked for immediate use.
Frequently Asked Questions
It allows the leadership to balance its 35 percent oral care market dominance with aggressive growth targets in high-margin beauty and pharma segments. By monitoring 45 key indicators across global plants, EPL maintains consistent 18 percent EBITDA margins. The framework also aligns internal manufacturing processes with the evolving sustainability demands of Fortune 500 consumer brands.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.